Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958880 · ClinicalTrials.gov registry record · Phase 3
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
A Phase 3 study of Social Anxiety Disorder, sponsored by Southern Methodist University.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT00958880 is a Phase 3 study of Social Anxiety Disorder that has completed, run by Southern Methodist University. The registered enrollment target is 40 participants, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00958880, a Phase 3 study of Social Anxiety Disorder, has completed, sponsored by Southern Methodist University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the utility of Yohimbine hydrochloride for facilitating fear extinction in a sample of patients with social phobia who will be treated with CBT.
Conditions Studied
Interventions
- DRUG Yohimbine Hydrochloride
- DRUG Sugar Pill
- BEHAVIORAL Group Cognitive Behavioral Therapy
Study Locations (2)
Massachusetts
- Boston University - Boston
Texas
- Southern Methodist University - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958880
The ClinicalTrials.gov registry entry for NCT00958880 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 159-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (75% lower). The listed sponsor is Southern Methodist University, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Yohimbine Hydrochloride is the first listed.
NCT00958880 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00958880 about?
NCT00958880 is a clinical study titled "Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety". The purpose of this study is to investigate the utility of Yohimbine hydrochloride for facilitating fear extinction in a sample of patients with social phobia who will be treated with CBT.
What is the current status of trial NCT00958880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2009-03. Estimated completion is 2013-01.
What conditions does trial NCT00958880 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT00958880?
The interventions under investigation include: Yohimbine Hydrochloride (DRUG), Sugar Pill (DRUG), Group Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00958880?
This trial is sponsored by Southern Methodist University, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00958880 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
COMPLETED · Phase 3
-
Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.